K2 HealthVentures

K2 HealthVentures is a long-term provider of debt and equity capital to venture and growth stage companies in the life sciences and healthcare industries.

[K2 HealthVentures @K2HVenture]

This week  @LS_Cares launched a Health Equity Portfolio Co-Investment Program and we are proud that our foundation is able to support their efforts to address health inequities among low-income families and communities in Greater Boston.
Learn more: https://t.co/f6mfCKASm3

[K2 HealthVentures @K2HVenture]

K2HV attended the @LS_Cares Impact Breakfast & was awarded the Luke Timmerman Impact Award for serving as an anchor investor in LSC’s new Health Equity initiative. Thank you to all those joining in our efforts to improve health equity & thank you @ldtimmerman for the honor.

[K2 HealthVentures @K2HVenture]

As we enter 2024, our team would like to reflect on K2HV’s progress and accomplishments. Learn more in our Year End Letter: https://t.co/0U7cqoxaT5

[K2 HealthVentures @K2HVenture]

We are thrilled to partner with new portfolio company @AcumenPharm, a clinical-stage drug development company developing a novel therapeutic for #Alzheimers. This loan agreement will provide operational flexibility & will help fund corporate initiatives: https://t.co/63mRBaRtjJ

[K2 HealthVentures @K2HVenture]

Today we are thrilled to partner with new portfolio company @mindmedco on a $50M credit facility to advance their portfolio of product candidates across an array of disorders of the brain.

Read more: https://t.co/zofv1PpoC8

[K2 HealthVentures @K2HVenture]

Great to spend time and chat with Bernat Olle and @mattpillar. https://t.co/HNvy39f76K

[Bernat Olle 🇺🇦 @bernatolle]

In this episode of the Business of Biotech, Parag Shah and I discuss with ⁦@mattpillar⁩ ins and outs of the fundraising process and how we came to work together, starting with ⁦@ldtimmerman⁩’s Presidential Traverse https://t.co/txz2F8yXqa

[K2 HealthVentures @K2HVenture]

How do you align the cultural & strategic elements of a #biotech financing deal? Tune in to hear K2HV CEO & Founding Managing Director @pshah333 and @bernatolle, CEO of portfolio company @VedantaBio, on the #BusinessofBiotech podcast: https://t.co/tPvtyEywKu @mattpillar

[K2 HealthVentures @K2HVenture]

Congrats to long-term partner @TScan_Tx for raising $140M to advance new T cell therapies for the treatment of cancer. We’re proud to continue supporting the TScan team as they evolve their TCR-T pipeline in hematologic malignancies and solid tumors: https://t.co/mY9kRICHAv

[K2 HealthVentures @K2HVenture]

Attending #BIO23? Tune in to a panel, “Beyond Equity: Extreme Innovation in Financing for Public Biotechs” moderated by K2HV Founding Managing Director & CIO Anup Arora on Mon., June 5 at 3:30pm ET. Learn more about this business of #biotech conversation: https://t.co/blpHMSgniz

[K2 HealthVentures @K2HVenture]

We believe Vedanta has developed a game-changing approach. Congrats to Bernat Olle and the Vedanta Team! https://t.co/UmFok9B0NH

[K2 HealthVentures @K2HVenture]

Congratulations to new portfolio company @VedantaBio on a $106.5M financing to support their novel pipeline of rationally-defined microbiome therapeutics, including the Phase 3 development for their lead program. Read more: https://t.co/xwWlyXQl6V

[K2 HealthVentures @K2HVenture]

K2HV proudly participated in a $25M preferred equity financing for clinical-stage immuno-oncology company @HarpoonTx to support the development of the Company's novel T cell engagers & to reach key data milestones from its clinical studies: https://t.co/PTDvBTjX5I

[K2 HealthVentures @K2HVenture]

SVB has been an important part of the innovation ecosystem. We are saddened by the events over the last week and the impact it has had across our network. See our statement on K2HV’s continued commitment to the life sciences and healthcare sectors: https://t.co/LXFgwz34T0

[Inari @Inari_Ag]

"We are at the beginning for what we can discover," said our CEO @P_Trivisvavet on the @WorldAgriTech stage this afternoon, where she joined a panel discussion on how the #agriculture industry can leverage existing knowledge and tools to innovate in gene-editing technology.

[K2 HealthVentures @K2HVenture]

K2HV is proud to continue our support of long-term portfolio company @ASLANpharma by participating in a $20M equity financing led by BVF Partners with the potential to receive up to an additional $80M. Read more: https://t.co/qMti3E5PCd

[Life Science Cares @LS_Cares]

First, he summitted the peaks of the White Mountains to support LSC. Now, Parag Shah from K2 HealthVentures has joined our Board of Advisors and underlined his commitment to doing good while doing well. Welcome, Parag! #LSCImpact #CaringActively

[K2 HealthVentures @K2HVenture]

Through effectively leveraging their Precision Psychiatry Platform, Alto is at the forefront of discovering and developing truly differentiated medicines for a variety of people living with mental health conditions https://t.co/P1Ztrndd1k

[K2 HealthVentures @K2HVenture]

We’re excited to add @AltoNeuro, an innovative company pioneering precision psychiatry, to our growing portfolio. K2HV has partnered on a $35M credit facility to support the advancement of its clinical-stage pipeline of precision medicines for the brain: https://t.co/BAKRwIgiVE

[K2 HealthVentures @K2HVenture]

#nash https://t.co/p4GUjRlYOf